| abstract |
The present disclosure provides methods and compositions for enhancing the treatment of a cancer, particularly in a human subject, by administering antibody drug conjugates (ADCs) to inhibit or kill specific myeloid/monocyte/macrophage-lineage cells. The myeloid/monocyte/macrophage-lineage cells are identified, for example, by expression of one or more of the scavenger receptors CD204 and CD163, and/or mannose receptor-1 (CD206). |